Table 4.
Prospective randomized trials of taxane/platinum vs taxane/anthracycline in early triple-negative breast cancer.
| Study (Author/Year) | Ref | Treatment | Dz Setting | Phase | N | Outcomes |
|---|---|---|---|---|---|---|
| Zhang P 2016 (published) | 117 |
Six cycles of q3w Paclitaxel (175 mg/m2 q3) carboplatin (AUC 5) vs Paclitaxel (175 mg/m2) Epirubicin (75 mg/m2) |
NAC | II | 91 |
pCR non-anthracycline: 39% anthracycline: 14% (p = 0.014) 3-year RFS (median follow up 55-months) non-anthracycline: 81% anthracycline: 62% (p = 0.043) |
| Najafi S 2017 (published) | 118 |
Q3w Docetaxel (70 mg/m2) plus Carboplatin (AUC 7) × 6 vs ACx4→docetaxel/carboplatin (same doses above) × 4 |
ADJ | II | 119 |
Median follow up 40 months 2-year DFS non-anthracycline: 93% anthracycline: 83% 2-year OS non-anthracycline: 97% anthracycline: 91% Estimated 5-year DFS non-anthracycline: 85% anthracycline: 64%, HR = 2.31; p = 0.028 5-year OS non-anthracycline: 92% anthracycline: 81% |
| Wang J 2019 (abstract) | 118 | Dose-dense paclitaxel/carboplatin vs Dose-dense EC→paclitaxel | ADJ | III | 132 |
3-year DFS non-anthracycline: 94% anthracycline: 78%, HR = 0.305, p = 0.0046 3-year OS non-anthracycline: 98% anthracycline: 93%, p = 0.0268 |
| Du F 2020 (published) | 120 |
Six cycles q3w Carboplatin AUC 5 Docetaxel 75 mg/m2 or paclitaxel 175 mg/m2 vs four cycles EC (epi: 90 mg/m2)→ docetaxel (75 mg/m2) or paclitaxel (175 mg/m2) |
ADJ | II | 308 |
Median follow up 66.9 months 5-year DFS non-anthracycline: 84.4% anthracycline: 85.8% p = 0.712 5-year OS non-anthracycline: 93.5% anthracycline: 94.4%, p = 0.770 |
| Zhang “NeoCART” 2020 (abstract) | 121 |
Six cycles q3w Docetaxel 75 mg/m2 Carboplatin AUC 6 vs Epirubicin (90 mg/m2)/Cytoxan x 4 → docetaxel (100 mg/m2) x 4 |
NAC | II | 88 |
pCR non-anthracycline : 61% anthracycline : 39%, p = 0.033 |
| Sharma P “NeoSTOP” 2021 (published) | 116 |
Six cycles Docetaxel 75 mg/m2 q3w Carboplatin AUC 6 q3w vs Paclitaxel 80 mg/m2 qw x 12 Carboplatin AUC 6 q3wx4→dose dense ACx4 |
NAC | II | 100 |
pCR: 54% both arms RCB 0/1: 67% each arm |
A doxorubicin, ADJ adjuvant, AUC area under the curve, C cyclophosphamide, DFS disease-free survival, E epirubicin, HR hazard ratio, MBC metastatic breast cancer, NAC neoadjuvant chemotherapy, pCR pathologic complete response, OS overall survival, RCB residual cancer burden index, RFS relapse-free survival.